Skip to main content
Premium Trial:

Request an Annual Quote

Proteome Sciences Reports 86 Percent Rise in 2013 Revenues


Proteome Sciences this week posted 2013 revenues of £2.14 million ($3.59 million), up 86 percent from £1.15 million in 2012.

The rise was driven by a 63 percent jump in year-over-year sales of the company's Tandem Mass Tag isobaric tagging reagents as well as a £1.25 million licensing and research deal with Thermo Fisher Scientific around TMT workflows. The company's 2013 grant revenue was £220,000, down 37 percent from £350,000 in 2012.

In a statement accompanying release of the results, CEO Christopher Pearce noted that the company continued this year to make progress across its three main areas of activity – biomarker services, internal biomarker development, and TMT reagent sales. In particular, he said, 2014 TMT sales growth is currently running at roughly double 2013 levels.

Proteome Sciences' net loss for the year was £3.15 million, or 1.62 pence per share, down 26 percent from £4.25 million, or 2.21 pence per share in 2012.

Expenses for the year were £4.92 million, down 2 percent from £5.01 million in 2012.

The company ended the year with £600,262 in cash and cash equivalents.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.